A patient with chronic constipation, normal TSH, and taking a calcium‑channel blocker (e.g., amlodipine) – what is the next step in management?

Management of Chronic Constipation with Normal TSH

In a patient with chronic constipation and normal TSH who is taking a calcium-channel blocker like amlodipine, first discontinue or substitute the offending medication if clinically feasible, then initiate polyethylene glycol (PEG) 17 g twice daily as first-line pharmacologic therapy. 1, 2

Step 1: Address Medication-Induced Constipation

• Calcium-channel blockers are a well-recognized cause of constipation and should be discontinued or switched to an alternative antihypertensive agent when possible. 2, 3
• This is the most important initial step, as continuing the offending medication will undermine any laxative therapy you prescribe. 2
• If blood pressure control requires continuation of the calcium-channel blocker, proceed directly to pharmacologic management while acknowledging this will be an ongoing challenge. 2

Step 2: Confirm Adequate Initial Workup

• A single complete blood count is sufficient laboratory testing in the absence of alarm features; routine TSH, calcium, and glucose panels are not cost-effective and have low diagnostic yield. 2
• Since TSH is already normal, no further thyroid evaluation is needed. 2, 4
• Perform a digital rectal examination in the left lateral position to assess for fecal impaction and evaluate pelvic floor motion during simulated defecation. 2
• Note that a normal digital rectal exam does NOT rule out pelvic floor dysfunction—specialized testing may still be required if first-line therapies fail. 2

Step 3: Initiate First-Line Pharmacologic Therapy

Polyethylene Glycol (PEG) is the preferred first-line agent with a strong recommendation based on moderate-quality evidence: 1

• Dose: PEG 17 g dissolved in 8 oz water, taken twice daily. 2
• PEG has demonstrated durable response over 6 months with moderate-quality evidence supporting its use. 1
• Common side effects include abdominal distension, loose stool, flatulence, and nausea, but these are generally well-tolerated. 1
• PEG is superior to other osmotic agents (lactulose, magnesium salts) in efficacy, tolerability, and safety, particularly in elderly patients. 2

Alternative osmotic agents if PEG is unavailable or not tolerated: 2

• Magnesium oxide can be considered (conditional recommendation, very low certainty), but avoid in renal insufficiency due to hypermagnesemia risk. 1, 2
• Lactulose 30–60 mL two to four times daily is an option for patients who fail or are intolerant to over-the-counter therapies, though bloating and flatulence are dose-dependent and may limit use. 1, 2

Step 4: Consider Fiber Supplementation (Adjunctive or Mild Cases)

• Fiber supplements can be used as first-line therapy for mild constipation, particularly in individuals with low dietary fiber intake. 1
• Among fiber supplements, only psyllium appears effective; data on bran and inulin are very limited and uncertain. 1
• Adequate hydration (8–10 oz fluid with each dose) must be ensured, as fiber without sufficient fluid can worsen constipation. 2, 3
• Flatulence is a commonly observed side effect. 1
• A trial of fiber can be considered before PEG use or in combination with PEG for mild constipation. 1

Step 5: Escalate to Stimulant Laxatives if Osmotic Therapy Fails

If PEG alone is insufficient after an adequate trial (typically 4–6 weeks), add a stimulant laxative: 1, 2

• Bisacodyl 10–15 mg once daily (up to three times daily) OR senna 2–3 tablets two to three times daily. 2
• The goal is one non-forced bowel movement every 1–2 days. 2, 3
• Bisacodyl and sodium picosulfate have strong recommendations for short-term use (≤4 weeks) or as rescue therapy, though long-term use is probably appropriate. 1
• Do NOT use docusate (stool softener)—it provides no additional benefit when combined with stimulant laxatives. 2

Important caveat: Oral bisacodyl is ineffective in the presence of fecal impaction; perform digital rectal examination first and consider rectal bisacodyl suppositories (10 mg) if moderate fecal burden is identified. 2

Step 6: Third-Line Secretagogue Therapy

If combination osmotic-stimulant therapy fails, escalate to prescription secretagogues: 2

• Linaclotide (guanylate cyclase-C agonist) or lubiprostone (chloride channel activator) are FDA-approved for chronic idiopathic constipation. 2, 5
• Plecanatide is another guanylate cyclase-C agonist option. 1
• These agents not only increase bowel movement frequency but also address straining, bloating, and satisfaction with bowel function. 5

Step 7: Prokinetic Agent for Refractory Cases

Prucalopride (selective 5-HT₄ receptor agonist) is recommended for refractory chronic constipation unresponsive to laxatives: 2, 5

• It is effective and generally well-tolerated, with transient headache and mild gastrointestinal symptoms being the most common adverse effects. 2, 5
• This represents a selective prokinetic approach when all other pharmacologic options have been exhausted. 5

Step 8: Referral for Specialized Testing

Refer to gastroenterology for anorectal manometry, balloon expulsion testing, and colonic transit studies when patients fail both first-line osmotic laxatives AND second-line stimulant laxatives: 2

• Anorectal physiologic testing can uncover defecatory (pelvic floor) disorders, which respond better to biofeedback therapy than escalating laxative regimens. 2
• Colonic transit studies identify slow-transit constipation, which may necessitate prokinetic agents or, in highly selected refractory cases, surgical intervention. 2

Common Pitfalls to Avoid

• Do not order routine metabolic panels (TSH, calcium, glucose) without specific clinical suspicion—they are not cost-effective. 2
• Do not prescribe fiber supplements to patients with insufficient fluid intake or limited mobility, as this will worsen constipation. 2, 3
• Do not continue calcium-channel blockers without attempting substitution or at least acknowledging this as a primary driver of symptoms. 2, 3
• Do not assume a normal digital rectal exam rules out pelvic floor dysfunction—specialized testing may still be needed. 2
• Do not use docusate in combination with stimulant laxatives—it adds no benefit. 2